Over-expression and activity of COX-2 have been associated with more aggressive tumor phenotypes and worse prognosis in patients with breast, colon, head, neck, lung, and pancreatic cancer (Wang et al., 2014; Li et al., 2020). This evidence concerns the gene PTGS2 and familial pancreatic carcinoma.